Bioventus Inc.’s BVS surgical solutions business unit sales are expected to be in focus when the company reports its third-quarter 2023 results. Bioventus’ earnings beat estimates in one of the ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

It doesn’t have to be at Levy Rink, or any rink — some old school pond hockey would suffice for these two programs.

Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. These figures are ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio At 2 years after implantation, a fully ...

Bioventus Inc (NASDAQ:BVS) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $138.20 million, and the earnings are expected to come in at $0.03 per ...

Bioventus Inc. BVS announced the completion of its earlier-announced divestiture of the Advanced Rehabilitation business of its subsidiary, Bioness, yesterday. In October 2024, BVS inked a definitive ...

Bioventus advances orthobiologic solutions for musculoskeletal care as nasdaq 100 index discussions highlight medical technology firms.